http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H03277297-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4776af4ac2f7f31108979d25ca494e71 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-37 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-60 |
| filingDate | 1990-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b55354a156503ad206d46d41b7c1a121 |
| publicationDate | 1991-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-H03277297-A |
| titleOfInvention | Determination of recombinant-type human angiotensinogen |
| abstract | PURPOSE: To easily accomplish the title determination by determining angiotensin I formed by making human renin act on recombinant-type human angiotensinogen. n CONSTITUTION: Firstly, recombinant-type human angiotensinogen (A) is prepared by incubating animal cells produced by introducing animal cell manifestation vector incorporated with the cDNA of the component A. Secondly, angiotensin I (C) is obtained by reaction of the component A with human renin (B) in a buffer solution containing EDTA at a concentration of 5-10mM/l. Thirdly, the component C is labeled with e.g. 125 I into the 125 I-labeled component C (D). Fourthly, the component D is diluted with a buffer solution containing tris hydrochloric acid, bovine serum albumin and NaN 3 as preservative into a solution (E) at 1.5-3.75fmol. Thence, the component E is counted by radioimmunoassay, thus determining the recombinant-type human angiotensinogen. n COPYRIGHT: (C)1991,JPO&Japio |
| priorityDate | 1990-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 66.